This accelerated timeline is crucial for patients battling large B-cell lymphoma, as Cindy Perettie, head of the Gilead cell therapy business, emphasizes the urgency of treatment due to the aggressive nature of the disease. The reduced wait time for Yescarta could potentially be lifesaving for many patients, providing them with faster access to this vital therapy.
Yescarta has already been making waves in the market, notably outpacing Bristol Myers Squibb’s rival drug, Breyanzi, in terms of product delivery efficiency. With the latest manufacturing improvements, Yescarta sets a new industry benchmark with its 14-day median turnaround time, significantly shorter than the 24 days targeted by Breyanzi.
However, the impact of manufacturing time on patient treatment is profound. Clinical trials have shown that the time taken to produce individualized therapies can result in disease progression for some patients while they wait. In Gilead’s ZUMA-7 trial, for instance, a small proportion of patients could not receive Yescarta due to the advancement of their condition during the manufacturing period.
Experts in the field, like David Porter from Penn Medicine, acknowledge the importance of these advancements. While he suggests that the reduction from 16 to 14 days might not be a major clinical leap, he agrees that any reduction in time is beneficial in preventing cancer progression.
Behind the scenes, this manufacturing efficiency is driven by Gilead and Kite’s efforts to optimize their processes, aiming to reduce quality control testing and processing steps. Chris McDonald, Kite’s global head of technical operations, points out that these enhancements are expected to lower overall costs and boost manufacturing capacity at their facilities in the United States. However, the specifics of these process improvements remain confidential, part of Gilead and Kite’s strategy to maintain their competitive edge.
While this update currently applies only within the United States, with international implementation pending additional regulatory approvals, it represents a significant stride in CAR-T therapy. Before this update, Gilead was already leading the race with the fastest turnaround times for its cell therapies, including Yescarta and Tecartus.
As the field of CAR-T therapy continues to evolve, Gilead’s latest achievement in reducing the manufacturing time of Yescarta stands out as a testament to the ongoing efforts to enhance cancer treatment and patient care. This development not only sets a new standard in the efficiency of delivering life-saving therapies but also underscores the importance of continual innovation in the fight against cancer.
1. https://endpts.com/gilead-kite-shorten-yescarta-manufacturing-by-two-days-in-incremental-improvement/
2. https://www.fiercepharma.com/manufacturing/gileads-kite-wins-fda-nod-new-car-t-manufacturing-process-speed-yescarta-turnaround?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FiercePharmaManufacturing&oly_enc_id=4567B8987523J5I
3. https://www.gilead.com/news-and-press/press-room/press-releases/2023/12/us-fda-approves-label-update-for-kites-yescarta-car-tcell-therapy-to-include-overall-survival-data
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services